Can the duration of triple therapy in patients with chronic hepatitis C be defined by the response to treatment, if the duration of the Lead-In phase has been longer than 4 weeks?
In Ukraine, patients are treated with pegylated interferon (PEG-IFN), ribavirin (R) and boceprevir (B) at their’s own expenses and therefore the lead-in phase of the therapy with PEG-IFN + R can be more than 4 weeks, as defined in the leaflet to B. Paper shows that in this case, decision on the duration of the subsequent treatment with PEG-IFN + R + B depending on the duration of the lead-in phase and virologic response to the treatment with two medications.